TVS Motor Q4 Results: TVS Motor posted a strong Q4FY26 with net profit up 19% to Rs 772 crore and revenue ...More

TVS Motor Q4 Results: TVS Motor posted a strong Q4FY26 with net profit up 19% to Rs 772 crore and revenue rising 30% to Rs 15,053 crore. Overall sales grew 28% to 15.6 lakh units, driven by robust motorcycle, scooter and EV volumes, even as profit dipped sequentially. ...Less

Cipla Q1 Results: Cipla reported a 10% YoY increase in consolidated net profit, reaching Rs 1,298 crore f ...More

Cipla Q1 Results: Cipla reported a 10% YoY increase in consolidated net profit, reaching Rs 1,298 crore for the June quarter, driven by a 4% rise in revenue from operations to Rs 6,957 crore. EBITDA stood at Rs 1,778 crore, reflecting a slight margin dip to 25.6%. The company's profit before tax reached Rs 1,770 crore. ...Less

The pharmaceutical major reported a 27 per cent rise in income from operations to Rs. 5,504 crore for the ...More

The pharmaceutical major reported a 27 per cent rise in income from operations to Rs. 5,504 crore for the quarter ended June, which was also sharply higher than analysts’ expectations. ...Less

Cipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in ...More

Cipla Q1 Results: The profit beat the ET Now Poll estimates of Rs 1,071 crore. Revenue from operations in the reporting period increased 6% year-on-year to Rs 6,694 crore. EBITDA saw a 14% year-on-year increase, reaching Rs 1,716 crore. This growth was primarily driven by the One India business' branded prescription division, which experienced a 10% growth. This growth was particularly strong in focused chronic therapies like respiratory, cardiac, and urology, outpacing the market. The overall chronic mix in the portfolio also improved by 106 basis points year-on-year, reaching 61.5%. ...Less

However, the profit figure managed to beat Rs 601 crore figure anticipated by analysts in an ET NOW poll. ...More

However, the profit figure managed to beat Rs 601 crore figure anticipated by analysts in an ET NOW poll. An ET NOW poll had anticipated the profit figure at Rs 601 crore. ...Less

Consolidated operating profit, calculated as earnings before interest, taxes, depreciation, and amortizat ...More

Consolidated operating profit, calculated as earnings before interest, taxes, depreciation, and amortization (EBITDA), grew by 31% on year to Rs 1,494.02 crore. Operating margin expanded a sharp 234 basis points to 23.6%. ...Less

Cipla expects to finish FY24 with 23-23.5% EBITDA margins and more than 10% revenue growth. Robust sales ...More

Cipla expects to finish FY24 with 23-23.5% EBITDA margins and more than 10% revenue growth. Robust sales growth in the US, India, and South Africa have contributed to Q1 2023’s 45.1% YoY net profit jump. Cipla reports the price erosion in the US market has stabilised, logistics' costs and raw material prices ...Less

Centrum expects South Africa and RoW also to remain under pressure in terms of growth and R&D spend to re ...More

Centrum expects South Africa and RoW also to remain under pressure in terms of growth and R&D spend to remain higher around 8 per cent of sales. ...Less

Revenue for the quarter increased mere 1.26 per cent YoY to Rs 3,894.46 crore. ...More

Revenue for the quarter increased mere 1.26 per cent YoY to Rs 3,894.46 crore. ...Less

Revenue for the quarter rose mere 1.26 per cent YoY to Rs 3,894.46 crore. ...More

Revenue for the quarter rose mere 1.26 per cent YoY to Rs 3,894.46 crore. ...Less

Total Income from operations stood at Rs 3,939 crore in June quarter. ...More

Total Income from operations stood at Rs 3,939 crore in June quarter. ...Less

Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year gro ...More

Cipla's North American business achieved a record $250 million revenue in Q1 FY25, a 13% year-on-year growth. The company's branded prescription business in India grew 10%, while overall India growth was offset by trade generics softness. Cipla's South Africa revenue grew 19% YoY in local currency terms. Net profit rose 17.4% to Rs 1,178 crore. ...Less

Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for ...More

Cipla shares: Following the earnings announcement, several brokerage firms revised their target price for the stock, with some estimates reaching as high as Rs 1,875 per share, indicating potential for further upside. ...Less

The company posted a net profit of Rs 566.04 crore in quarter ended June, an increase of 26.6 per cent fr ...More

The company posted a net profit of Rs 566.04 crore in quarter ended June, an increase of 26.6 per cent from a year ago. ...Less

In morning session, the scrip was trading 8.5% higher at Rs 1.160 on BSE. Meanwhile, in the last one year ...More

In morning session, the scrip was trading 8.5% higher at Rs 1.160 on BSE. Meanwhile, in the last one year, it has surged 19%. ...Less

Q4 results today: Several other companies scheduled to release their financial results include Cholamanda ...More

Q4 results today: Several other companies scheduled to release their financial results include Cholamandalam Finance, Eicher Motors, Finolex Industries, Jupiter LifeLine Hospitals, Kalyan Jewellers, Piramal Pharma, Punjab and Sind Bank, Spencers Retail, TCI Express, Thermax, and more. ...Less

Nirmal Bang expects the company to report a 45 per cent decline in net profit at Rs 262.80 crore on a 0.8 ...More

Nirmal Bang expects the company to report a 45 per cent decline in net profit at Rs 262.80 crore on a 0.8 per cent fall in net sales at Rs 3,958 crore. ...Less

The company had reported a net profit of Rs 447.15 crore in the same quarter a year ago. An ET Now poll h ...More

The company had reported a net profit of Rs 447.15 crore in the same quarter a year ago. An ET Now poll had expected the company to report a drop in profit to Rs 310 crore. ...Less

Cipla's June quarter earnings are anticipated to reveal a mixed performance, with robust India sales part ...More

Cipla's June quarter earnings are anticipated to reveal a mixed performance, with robust India sales partially offsetting challenges in the US generics market. Revenue is expected to increase, while EBITDA margins may decline due to lower US contributions. Investor attention will be directed towards the US business trajectory, pricing dynamics, and the resurgence of India's trade generics segment. ...Less

Shares of drug major Cipla today gained over 6 per cent after the company reported 17.47 per cent increas ...More

Shares of drug major Cipla today gained over 6 per cent after the company reported 17.47 per cent increase in net profit for the July-September quarter. ...Less

Cipla Q2 Results: Revenue from operations increased 6% year-on-year to Rs 7,051 crore in July-September 2 ...More

Cipla Q2 Results: Revenue from operations increased 6% year-on-year to Rs 7,051 crore in July-September 2024, up from Rs 6,678 crore in the same period last year. The company reported a 12% year-on-year EBITDA growth to Rs 1,886 crore in Q2. The One India business grew 5% YoY, with the Branded Prescription segment continuing to outperform the market in major chronic therapies. ...Less

Cipla's Q3 revenue for the quarter grew 13.7% YoY to Rs 6,604 crore, compared to Rs 5,810 crore in the sa ...More

Cipla's Q3 revenue for the quarter grew 13.7% YoY to Rs 6,604 crore, compared to Rs 5,810 crore in the same quarter last year. However, the drugmaker saw a marginal decline from the previous quarter's revenue of Rs 6,678 crore. Meanwhile, its EBITDA surged 24.2% YoY to Rs 1,748 crore in the December quarter of FY24. ...Less

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reachi ...More

Drug major Cipla reported a 49% year-on-year jump in its December quarter consolidated net profit, reaching Rs 1,571 crore, compared to Rs 1,056 crore in the same period last year. The profit after tax (PAT) exceeded the ET Now poll estimate of Rs 1,302 crore. ...Less

The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla ...More

The bottomline was higher than the Rs 1,006 crore which was expected by analysts in an ET Now poll. Cipla's consolidated margin came in at 26% during the quarter. ...Less

Cipla reported Q1FY25 net profit expected between Rs 1,061-1,135 crore, with YoY growth of 6.5%-14%. Reve ...More

Cipla reported Q1FY25 net profit expected between Rs 1,061-1,135 crore, with YoY growth of 6.5%-14%. Revenue estimated at Rs 6,749-6,879 crore, up 7%-10% YoY. Analysts from Kotak, Axis, JM Financial, and InCred provide diverse profit and revenue expectations based on domestic sales, US contributions, and acquisitions. ...Less

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volu ...More

Q2 earnings for Maruti and Cipla are expected to be muted, with Maruti likely seeing a 2% decline in volumes and flat revenues, while net profit could drop up to 5%. Cipla may report 3-6% revenue growth and a 4-5.7% rise in net profit. ...Less

Bank of Baroda posted a modest 2% YoY rise in Q1 FY26 profit to ₹4,541 crore. Net interest income dipped ...More

Bank of Baroda posted a modest 2% YoY rise in Q1 FY26 profit to ₹4,541 crore. Net interest income dipped 1.4%, impacted by tax refund reclassification. Deposits and advances, both domestic and international, grew strongly year-on-year. ...Less

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter comp ...More

Shriram Finance Q1 Results: The profit after tax (PAT) increased slightly by 0.8% quarter-on-quarter compared to ₹2,139 crore in Q4FY25, while net interest income (NII) declined marginally by 0.41% sequentially from ₹6,051 crore in the same period. ...Less

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 n ...More

Motilal Oswal Q3 Results: Motilal Oswal Financial Services (MOFSL) reported a 14% YoY decline in Q3FY25 net profit to ₹565 crore despite a 12% rise in revenue. Sequentially, PAT dropped 50%, while segment performance showed mixed trends. ...Less

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenu ...More

Cipla Q2 Results: Cipla reported a 4% YoY growth in net profit to Rs 1,351 crore and an 8% rise in revenue to Rs 7,589 crore. The company saw strong performance in its India and North America businesses, with key products like Foracort and Albuterol leading. ...Less

The management expects the impact of COVID-19 to be short-lived and has guided for a recovery in the near ...More

The management expects the impact of COVID-19 to be short-lived and has guided for a recovery in the near term. ...Less

Cipla Q4 Results: The company’s revenue from operations grew by 8.45% year-on-year to Rs 6,597.72 crore, ...More

Cipla Q4 Results: The company’s revenue from operations grew by 8.45% year-on-year to Rs 6,597.72 crore, compared to Rs 6,082.37 crore in the corresponding quarter of the previous fiscal ...Less

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacte ...More

Cipla shares dropped 5% after reporting a 57% year-on-year decline in net profit to Rs 676 crore, impacted by a fall in gRevlimid sales. Revenue remained flat at Rs 7,074 crore, with EBITDA also declining. The company plans upcoming launches to offset revenue decline and drive future growth. ...Less

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, E ...More

Companies like Aarti Drugs, Amber Enterprises, Bandhan Bank, Cholamandalam Investment, City Union Bank, ESAF SFB, Equitas SFB, Mangalam Organics, Piramal Pharma, TTK Prestige among others will also declare their results. ...Less

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of th ...More

Cipla Q4 Results Preview: As per the combined projections of four brokerages, there's a possibility of the net profit for the fourth quarter surging by as much as 71% year-on-year, alongside an expected 7% year-on-year increase in net sales. ...Less